Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib with or without gemcitabine versus gemcitabine in advanced biliary tract cancer
2007-003056-12Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in biliary cancer, gallbladder cancer, extrahepatic cholangiocarcinoma (eCCA) and 2 more comparing Vandetanib monotherapy, Vandetanib plus gemcitabine and Gemcitabine plus vandetanib matching placebo (3 arms). Primary endpoint: Progression-free survival. Started Oct 2008; status: completed.
02
Drugs
vandetanibgemcitabine
03
Conditions
biliary cancergallbladder cancerextrahepatic cholangiocarcinoma (eCCA)intrahepatic cholangiocarcinoma (ICC)Ampullary cancer (AC)
Beyond the preview
Go deeper on 2007-003056-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003056-12.